Qing-Li He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing-Li He has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Yongjun Dang
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, China
19 shared publications - Cheng Shen
Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, China
16 shared publications - Di Zhu
Lab of Tumor Immunology, Department of Human Anatomy, Histology and Embryology, Basic Medical School of Fudan University, Shanghai, China
16 shared publications - Fanghui Lu
Institute of Life Sciences, Chongqing Medical University, Chongqing, China
16 shared publications - Haiyang Li
The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
16 shared publications - Jianbo Pan
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
16 shared publications
Latest Publications
- 5 July 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
Heterologous Expression of an Abandoned Termite Mound Fungus Gene Cluster Reveals a Protective Aldehyde–Alcohol Cycle and a Candidate Termiticidal Metabolite
The medicinal fungus Wulingshen, comprising multiple Xylaria species, inhabits deserted termite mounds as sclerotia. To explore the molecular basis of its niche adaptation, we employed a synthetic biology-driven approach. Metagenomic and transcriptomic mining of wild specimens identified a conserved biosynthetic gene cluster. Its heterologous reconstruction in the fungal host Aspergillus oryzae enabled the characterization of a family of α-pyrone metabolites and, crucially, the elucidation of a spatially separated aldehyde-alcohol cycle. In this self-protection system, an extracellular oxidase (WlsA) converts an alcohol precursor to a reactive aldehyde, while an intracellular reductase (WlsE) catalyzes the reverse reaction. The aldehyde product exhibits potent toxicity against termites in vitro, suggesting a potential role in ecological interactions. This work establishes a functional genomics platform that decodes cryptic ecological metabolism by integrating multiomics with heterologous pathway expression, providing a generalizable strategy for discovering and mechanistically understanding niche-specific natural products.
- 5 July 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
Heterologous Expression of an Abandoned Termite Mound Fungus Gene Cluster Reveals a Protective Aldehyde–Alcohol Cycle and a Candidate Termiticidal Metabolite
The medicinal fungus Wulingshen, comprising multiple Xylaria species, inhabits deserted termite mounds as sclerotia. To explore the molecular basis of its niche adaptation, we employed a synthetic biology-driven approach. Metagenomic and transcriptomic mining of wild specimens identified a conserved biosynthetic gene cluster. Its heterologous reconstruction in the fungal host Aspergillus oryzae enabled the characterization of a family of α-pyrone metabolites and, crucially, the elucidation of a spatially separated aldehyde-alcohol cycle. In this self-protection system, an extracellular oxidase (WlsA) converts an alcohol precursor to a reactive aldehyde, while an intracellular reductase (WlsE) catalyzes the reverse reaction. The aldehyde product exhibits potent toxicity against termites in vitro, suggesting a potential role in ecological interactions. This work establishes a functional genomics platform that decodes cryptic ecological metabolism by integrating multiomics with heterologous pathway expression, providing a generalizable strategy for discovering and mechanistically understanding niche-specific natural products.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of glycoprotein patterns in MDA-MB-231 cells after treatment with the indicated concentrations of penfluridol for 24 hours. Red arrowhead, immature glycoproteins. (b) Western blot analysis of protein expression pattern of ACE2 in HEK293T cells after treatment with the indicated concentrations of penfluridol for 24 hours. (c) In HEK293T cells, FLAG-tagged ACE2 was treated for 24 hours, collected by immunoprecipitation, subjected to SDS-PAGE, and analyzed by western blot. (d) Pearson correlation coefficient of three independent groups of (c) through N-glycan profiling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of glycoprotein patterns in MDA-MB-231 cells after treatment with the indicated concentrations of penfluridol for 24 hours. Red arrowhead, immature glycoproteins. (b) Western blot analysis of protein expression pattern of ACE2 in HEK293T cells after treatment with the indicated concentrations of penfluridol for 24 hours. (c) In HEK293T cells, FLAG-tagged ACE2 was treated for 24 hours, collected by immunoprecipitation, subjected to SDS-PAGE, and analyzed by western blot. (d) Pearson correlation coefficient of three independent groups of (c) through N-glycan profiling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- Open Access
A Substrate-Dependent Bifunctional Dioxygenase from Fraxinus chinensis for O-Demethylation and C8-Hydroxylation of Coumarins
Fraxinus chinensis Roxb. (Qinpi), a traditional Chinese medicinal plant, accumulates abundant coumarins that contribute to its anti-inflammatory and other bioactivities. However, the enzymatic basis for coumarin structural diversification in this species remains largely unexplored. Here, through transcriptome-wide identification of the 2-oxoglutarate-dependent dioxygenase (2OGD) family in F. chinensis, followed by phylogenetic analysis, heterologous expression, and in vitro enzyme assays, we identified FcDOH2, a member of the DOXC31 subfamily, which exhibits substrate-dependent bifunctionality, catalyzing the C6-O-demethylation of scopoletin (3) to esculetin (2) and the C8-hydroxylation of umbelliferone (1) to daphnetin (6). Using AlphaFold3-based structural modeling, molecular docking, and alanine scanning mutagenesis, we revealed that residues R155 and R221 are essential for both activities through stabilizing hydrogen bonds, whereas residue F312 acts as a functional switch, being critical for demethylation but negatively regulating hydroxylation. These findings uncover a rare bifunctional 2OGD with substrate-dependent catalytic plasticity, providing mechanistic insights into coumarin diversification in medicinal plants and a structural basis for future enzyme engineering.
Open AccessA Substrate-Dependent Bifunctional Dioxygenase from Fraxinus chinensis for O-Demethylation and C8-Hydroxylation of Coumarins
Fraxinus chinensis Roxb. (Qinpi), a traditional Chinese medicinal plant, accumulates abundant coumarins that contribute to its anti-inflammatory and other bioactivities. However, the enzymatic basis for coumarin structural diversification in this species remains largely unexplored. Here, through transcriptome-wide identification of the 2-oxoglutarate-dependent dioxygenase (2OGD) family in F. chinensis, followed by phylogenetic analysis, heterologous expression, and in vitro enzyme assays, we identified FcDOH2, a member of the DOXC31 subfamily, which exhibits substrate-dependent bifunctionality, catalyzing the C6-O-demethylation of scopoletin (3) to esculetin (2) and the C8-hydroxylation of umbelliferone (1) to daphnetin (6). Using AlphaFold3-based structural modeling, molecular docking, and alanine scanning mutagenesis, we revealed that residues R155 and R221 are essential for both activities through stabilizing hydrogen bonds, whereas residue F312 acts as a functional switch, being critical for demethylation but negatively regulating hydroxylation. These findings uncover a rare bifunctional 2OGD with substrate-dependent catalytic plasticity, providing mechanistic insights into coumarin diversification in medicinal plants and a structural basis for future enzyme engineering.
- 15 May 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (21) , 6607-6612
3D Probe-Based Chemoproteomic Profiling Enables the Discovery of a Polyphenol Oxidase Catalyzing Oxidative Lactonization of Salvianolic Acid B
Chemoproteomic profiling provides a complementary approach for linking natural products to their corresponding enzymes. A previously unrecognized polyphenol oxidase, SmPPOA, was identified from Salvia miltiorrhiza using a 3D carbene-immobilized salvianolic acid B. SmPPOA catalyzes oxidative lactonization of salvianolic acid B to generate salvianolic acid O via a cascade of oxidation and intramolecular Michael addition using the carboxylate anion as the Michael donor. This strategy can facilitate discovery of biosynthetic enzymes for plant natural products.
- 15 May 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (21) , 6607-6612
3D Probe-Based Chemoproteomic Profiling Enables the Discovery of a Polyphenol Oxidase Catalyzing Oxidative Lactonization of Salvianolic Acid B
Chemoproteomic profiling provides a complementary approach for linking natural products to their corresponding enzymes. A previously unrecognized polyphenol oxidase, SmPPOA, was identified from Salvia miltiorrhiza using a 3D carbene-immobilized salvianolic acid B. SmPPOA catalyzes oxidative lactonization of salvianolic acid B to generate salvianolic acid O via a cascade of oxidation and intramolecular Michael addition using the carboxylate anion as the Michael donor. This strategy can facilitate discovery of biosynthetic enzymes for plant natural products.
- 2 July 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 128, 130319
Natural products targeting the NF-κB signaling pathway:Potential therapeutic drug candidates
- 2 July 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 128, 130319
Natural products targeting the NF-κB signaling pathway:Potential therapeutic drug candidates
- 17 April 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (17) , 4574-4579
Biocatalytic Synthesis of Corticosteroid Derivatives by Toad-Derived Steroid C21-Hydroxylase
CsCYP21A, a steroid 21-hydroxylase from Bufo bufo gargarizans, exhibits unprecedented sequential oxidations. Optimizing Pichia pastoris biotransformation conditions enhanced C21-hydroxylation selectivity, converting 14 substrates to 21-hydroxylated products, with 10 conversions of >80% and 4 yields of >80%. Hydrocortisone production reached 1.5 g L-1 day-1 with 100 g/L wet biomass. CsCYP21A's versatility enables integration into the synthesis of over 10 steroidal drugs, offering a sustainable biocatalytic platform for green pharmaceutical manufacturing.
- 17 April 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (17) , 4574-4579
Biocatalytic Synthesis of Corticosteroid Derivatives by Toad-Derived Steroid C21-Hydroxylase
CsCYP21A, a steroid 21-hydroxylase from Bufo bufo gargarizans, exhibits unprecedented sequential oxidations. Optimizing Pichia pastoris biotransformation conditions enhanced C21-hydroxylation selectivity, converting 14 substrates to 21-hydroxylated products, with 10 conversions of >80% and 4 yields of >80%. Hydrocortisone production reached 1.5 g L-1 day-1 with 100 g/L wet biomass. CsCYP21A's versatility enables integration into the synthesis of over 10 steroidal drugs, offering a sustainable biocatalytic platform for green pharmaceutical manufacturing.